openPR Logo
Press release

SMi’s 2nd annual Highly Potent Active Pharmaceutical Ingredients Conference Hosts 2 Interactive Workshops

04-12-2018 11:44 AM CET | Science & Education

Press release from: SMi Group

/ PR Agency: Westminster Bridge Road
SMi’s 2nd annual Highly Potent Active Pharmaceutical

The Highly Potent Active Pharmaceutical Ingredients conference will be hosting 2 interactive half day post-conference workshops on the 23rd May, presented by HPAPI Project Services Limited and Affygility Solutions LLC.

Workshop A: Practical Steps for Delivering HPAPI Projects

Time: 08:30 - 12:30

Workshop Overview:

Biopharmaceutical companies embody application of the scientific method to identify and deliver new patient therapies. The same systematic, scientific principles should be used to develop and deliver research, development and production facilities that are fit for purpose and which protect healthy workers.

This workshop will explore key HPAPI project elements in a stepwise manner, helping define and deliver HPAPI projects that are technically sound, based on justifiable data which can underpin robust and defensible investment.

Why Attend:

Learn key HPAPI project elements, what factors are important and how to build information designed to underpin HPAPI project investments. All too often companies and their advisors, design and deliver HPAPI facilities based on “emotion” and guesswork. This workshop will try to ditch the emotion and provide a pathway to systematic and scientific project design. The objective will be the delivery of efficient facilities with process matters at the centre and suitable and defensible worker protection measures integrated into and set around the process.

Workshop Leader:

- Justin Mason-Home, Director, HPAPI Project Services Limited

Workshop B: Preventing Cross Contamination & Employee Exposures in the context of HPAPIs

Time: 13:30 - 17:30

Workshop Overview:

This workshop will provide an overview of the regulatory basis for ADEs and PDEs, will discuss how they are determined and present the basics of preventing cross-contamination.

Why You Should Attend:

Since June of 2015, the EMA’s requirements for developing and implementing health-based exposure limits in multi-product pharmaceutical manufacturing facilities has been in effect. Unfortunately, there is still much confusion and misunderstandings on how these health-based limits are to be implemented. If your company handles multiple products in the same facility, this workshop is ideal.

Workshop Leader:

- Dean Calhoun, President/ CEO, Affygility Solutions LLC

Further information is available at: www.highlypotentapi.com/pr5

SMi presents the 2nd Annual:

Highly Potent Active Pharmaceutical Ingredients (HPAPI)
Date: 21st – 22nd May 2018
Workshops: 23rd May 2018
Location: Holiday Inn Kensington Forum, London UK
Website: http://www.highlypotentapi.com/pr5

---end---

Contact Information:

For all media inquiries contact Pav Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Westminster Bridge Road
1

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release SMi’s 2nd annual Highly Potent Active Pharmaceutical Ingredients Conference Hosts 2 Interactive Workshops here

News-ID: 1013549 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for HPAPI

Cytotoxic Drugs and HPAPI Manufacturing Market
Cytotoxic Drugs and HPAPI Manufacturing Market worth $27.1 Bn by 2031 - Exclusive Report by InsightAce Analytic InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Cytotoxic Drugs and HPAPI Manufacturing Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large, Very Large), Scale of Operation (Preclinical, clinical, commercial), Type of Molecule (Small molecules, biologics), Type of Highly Potent
HPAPI Market Player Profiling, Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market Size Forecast till 2028
According to Ameco Research 'HPAPI Market report, the analysts took this into account when estimating the HPAPI Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the HPAPI Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes HPAPI Market trends, segmentation, key companies, SWOT, PORTER and
HPAPI Market: Opportunities and Challenges
The global HPAPIs Market is projected to register a CAGR of 8.7% during the forecast period (2018-23). The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies and growing focus on precision medicine. However, factors such as the requirement of large investments, discrepancies in HPAPI banding
New Technologies for HPAPI Manufacturing and Containment
SMI Reports: With new technologies becoming available for the pharmaceutical industry, the HPAPI market is utilising these new innovations to simplify manufacturing processes reducing powder exposure and allowing a semi-continuous production. At this year's HPAPI USA Conference emerging manufacturing technologies will be one of the key points to be discussed along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures. Key highlights include: Alternative HPAPI manufacturing technologies to
The Latest Innovations in HPAPI Manufacturing Technologies
SMi’s inaugural Highly Potent Active Pharmaceutical Ingredients USA Conference, will focus on the latest innovative manufacturing technologies with a special spotlight presentation on effective and safe containment solutions for biologics based HPAPIs, along with cleaning and cross contamination requirements. Keith Jensen, Owner and Consultant at Keith Jensen Consulting, previously at Novartis-MIT Center for Continuous Manufacturing, discusses alternative HPAPI manufacturing technologies to reduce powder exposure and improve safety enabling continuous manufacturing. Other